Legal Representation
Attorney
Nadine P. Flynn, Esq.
USPTO Deadlines
Application History
26 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| May 16, 2005 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| May 16, 2005 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Jun 18, 2004 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
| Jun 11, 2004 | CFIT | O | CASE FILE IN TICRS | Loading... |
| Jun 7, 2004 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jun 7, 2004 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
| Nov 25, 2003 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Nov 17, 2003 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 17, 2003 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Jul 2, 2003 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Jun 24, 2003 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jun 24, 2003 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Jan 7, 2003 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Nov 18, 2002 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 18, 2002 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| May 15, 2002 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| May 8, 2002 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 8, 2002 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Jan 22, 2002 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Oct 30, 2001 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Oct 10, 2001 | NPUB | O | NOTICE OF PUBLICATION | Loading... |
| Apr 23, 2001 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jan 11, 2001 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Nov 7, 2000 | CNRT | F | NON-FINAL ACTION MAILED | Loading... |
| Oct 27, 2000 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 24, 2000 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment of cardiovascular diseases, central nervous system diseases and disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005